Gabrielle Sulzberger, a director at Eli Lilly & Co, has acquired nearly four shares of the company’s common stock, valued at approximately $4,960. This acquisition, reported in a recent SEC filing, is part of the Lilly Directors' Deferral Plan, which allows directors to defer cash compensation in exchange for stock units. The transaction took place on October 19, 2026, and was filed with the SEC on October 20, 2026.
This move is significant as it highlights the ongoing commitment of board members to the company and reflects confidence in Eli Lilly's future growth. The pharmaceutical industry is highly competitive, with Eli Lilly continuing to be a key player in the sector, known for its innovative products and strategic initiatives.
Background
Sulzberger Gabrielle is a director at Eli Lilly & Co, which operates in the pharmaceutical preparations sector. The company is listed under the Central Index Key (CIK) number 0000059478. Eli Lilly is incorporated in Indiana and has its headquarters in Indianapolis. The company has a fiscal year ending on December 31.
What the Filing Says
According to the SEC filing, Sulzberger acquired 3.9976 shares of Eli Lilly common stock at a price of $1240.34 per share. Following this transaction, Sulzberger now owns a total of 3016.4449 shares of the company. The filing notes, "At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service."
Impact
This acquisition may affect shareholders and stakeholders in Eli Lilly, as it signals the board's confidence in the company's performance and future direction. The pharmaceutical sector, particularly companies like Eli Lilly, is closely watched by investors and analysts, making such transactions noteworthy.
What's Next
The filing does not say what happens next.